VVD-159642
- Generic Name
- VVD-159642
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT06804824
- Locations
- 🇺🇸
START Mid West, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain, Ogden, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath